title: Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma.
abstract: From 1987 to 1999 35 patients with poor prognosis non-Hodgkin's lymphoma (NHL) underwent allogeneic stem cell transplantation (SCT) at the University Hospitals of Vienna and Graz. Initial biopsy specimens were reclassified according to the Revised European-American Classification of Lymphoid Neoplasms (REAL). All patients surviving 28 days engrafted. Twenty-eight of them (93%) attained clinical remission. At the last follow-up 14 patients were alive and disease-free at a median of 5.0 (range, 2.3-12.9) years after allogeneic SCT. The actuarial overall survival is 35%. Five patients relapsed 1.8 to 27.6 months after transplant, the probability of relapse is 23%. Of the 21 deaths following SCT, seven were due to relapse/refractory disease and 14 due to transplant-related causes. The probability of treatment-related mortality is 48%. After SCT, minimal residual disease (MRD) was monitored by polymerase chain reaction (PCR) in seven patients with a BCL-2/IgH translocation and in 13 with a clonal immunoglobulin heavy chain (IgH) rearrangement. All 20 patients attained clinical remission rapidly and converted to PCR negativity. In the follow-up nine of these patients are in long-term clinical and molecular remission, six PCR-negative patients died of transplant-related causes and five patients relapsed. In summary, allogeneic stem cell transplantation has a curative potential for patients with refractory and recurrent non-Hodgkin's lymphoma. In our series long-term disease-free survival was associated with molecular disease eradication after SCT. Treatment-related mortality rate was high, thus earlier referral of selected patients to allogeneic SCT should be considered.
authors.affiliation: Department of Medicine I, University Hospital of Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Mitterbauer
authors.forename: P
authors.initials: P
authors.lastname: Neumeister
authors.forename: P
authors.initials: P
authors.lastname: Kalhs
authors.forename: S
authors.initials: S
authors.lastname: Brugger
authors.forename: G
authors.initials: G
authors.lastname: Fischer
authors.forename: K
authors.initials: K
authors.lastname: Dieckmann
authors.forename: P
authors.initials: P
authors.lastname: Hoecker
authors.forename: W
authors.initials: W
authors.lastname: Hinterberger
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.forename: I
authors.initials: I
authors.lastname: Simonitsch
authors.forename: U
authors.initials: U
authors.lastname: Jaeger
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: C
authors.initials: C
authors.lastname: Mannhalter
authors.forename: G
authors.initials: G
authors.lastname: Mitterbauer
authors.forename: H T
authors.initials: HT
authors.lastname: Greinix
mesh_terms: D000328:Adult; D005260:Female; D015321:Gene Rearrangement; D005803:Genes, Immunoglobulin; D019254:Genes, bcl-2; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011379:Prognosis; D014184:Transplantation, Homologous
chemical_list: D007143:Immunoglobulin Heavy Chains